Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Amneal Pharmaceuticals, Inc. - SIC # 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS SUNDRIES
Ticker
Exchange
SIC #
Website
Latest Ticker
AMRX
Nasdaq
5122
www.amneal.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Amneal Pharmaceuticals, Inc.
3 Overrated Stocks We Think Twice About
- Oct 9th, 2026 4:59 am
Amneal to Report Third Quarter 2026 Results on November 3, 2026
- Oct 8th, 2026 6:00 am
3 Low-Volatility Stocks with Open Questions
- Oct 5th, 2026 3:07 am
Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New Launches
- Oct 3rd, 2026 1:11 am
Why Is Amneal (AMRX) Stock Rocketing Higher Today
- Sep 21st, 2026 6:38 pm
Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Sep 18th, 2026 2:01 pm
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
- Sep 18th, 2026 12:00 pm
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
- Sep 17th, 2026 6:20 am
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)?
- Sep 5th, 2026 1:06 am
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats
- Sep 4th, 2026 12:48 pm
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism
- Sep 4th, 2026 10:13 am
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
- Sep 3rd, 2026 8:07 am
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
- Aug 27th, 2026 8:57 am
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
- Aug 27th, 2026 7:42 am
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
- Aug 26th, 2026 10:29 am
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
- Aug 26th, 2026 10:10 am
1 Stock Under $50 with Solid Fundamentals and 2 Facing Challenges
- Aug 26th, 2026 5:47 am
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
- Aug 25th, 2026 9:07 am
Here's Why You Should Add ACET Stock to Your Portfolio Now
- Aug 24th, 2026 8:09 am
Scroll